-
The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesotheliomaErčulj, Nina ...Objective: Identification of biomarkers that could predict gemcitabine efficacy and toxicity is a key issue in the development of individualized therapy. The aim of our study was to evaluate the ... influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma (MM). Methods: In total, 107 patients with MM, treated with gemcitabine-platinum chemotherapy, were genotyped for 11 polymorphisms in deoxycytidine kinase, ribonucleotide reductase M1 (RRM1), and cytidine deaminase genes using KASPar assays. Binary logistic regression was used to evaluate the influence of selected polymorphisms on tumor response and occurrence of treatment-related toxicity, while their influence on survival was estimated by Cox proportional hazards model. A haplotype analysis was carried out to assess the combined effect of RRM1 polymorphisms. Results: Deoxycytidine kinase and cytidine deaminase polymorphisms did not influence treatment outcome in patients with MM. In multivariable analysis, RRM1 2927A>Cpolymorphism significantly decreased overall survival probability šhazard ratio (HR)=2.02; 95% confidence interval (CI)=1.11-3.65; P=0.021đ. Twopromoter polymorphisms, RRM1 -524T>C and -37C>A, decreased the odds of nausea/vomiting grade>/=2 occurrence šodds ratio (OR)=0.25; 95% CI=0.10-0.60; P=0.002 and OR=0.26; 95% CI=0.11-0.63; P=0.003, respectivelyđ. RRM1 TTCCA haplotype was associated with worse tumor response (OR=16.67; 95% CI=2.38-100.00; P=0.004) and worse overall survival (HR=2.97; 95% CI=1.46-6.06; P=0.003) compared with the most frequent TTCAA haplotype, while TCACA haplotype influenced nausea/vomiting grade>/=2 occurrence (OR=0.27; 95% CI=0.12-0.60; P=0.001). Conclusion: RRM1 polymorphisms as well as haplotypes showed an association with gemcitabine treatment efficacy and toxicity; therefore, they should be validated as potential markers for the prediction ofclinical outcome in patients with MM.Source: Pharmacogenetics and genomics. - ISSN 1744-6872 (Vol. 22, iss. 1, 2012, str. 58-68)Type of material - article, component partPublish date - 2012Language - englishCOBISS.SI-ID - 29194201
Author
Erčulj, Nina |
Kovač, Viljem |
Hmeljak, Julija |
Franko, Alenka |
Dodič-Fikfak, Metoda |
Dolžan, Vita
Topics
Pleural neoplasms |
Mesothelioma |
Drug therapy |
Platinum |
Deoxycytidine |
Genotype |
Haplotypes |
Treatment outcome |
Deoxycytidine kinase |
Ribonucleotide reductases |
Cytidine deaminase |
Survival analysis |
Regression analysis |
Proportional hazards models |
Prsna mrena, novotvorbe |
Genotip |
Mezoteliom |
Deoksicitidin |
Platina |
Preživetje, analiza |
Proporcionalni modeli tveganja |
Ribonukleotidne reduktaze |
Deoksicitidinska kinaza |
Citidinska deaminaza |
Zdravljenje, izid |
Regresijska analiza |
Haplotipi
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|---|
Erčulj, Nina | 30705 |
Kovač, Viljem | 16229 |
Hmeljak, Julija | 29479 |
Franko, Alenka | 23759 |
Dodič-Fikfak, Metoda | 12218 |
Dolžan, Vita | 11711 |
Select pickup location:
Material pickup by post
Notification
Subject headings in COBISS General List of Subject Headings
Select pickup location
Pickup location | Material status | Reservation |
---|
Please wait a moment.